Table 4.
Use of HTN medication within 6 months from allograft IgAN Dx and its’ association with the risk of DCGF
| Univariable | Multivariable – model 1a | Multivariable – model 2b | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | Adjusted HR (95% CI) | P | Adjusted HR (95% CI) | P | |
| Single RAASB | Ref. | Ref. | Ref. | |||
| No medication | 0.15 (0.06–0.40) | < 0.001 | 0.17 (0.06–0.48) | 0.001 | 0.17 (0.06–0.49) | 0.001 |
| Single BB/CCB | 2.74 (1.16–6.47) | 0.02 | 3.05 (1.19–7.79) | 0.02 | 2.88 (1.13–7.37) | 0.03 |
| Combination | 2.76 (1.32–5.79) | 0.007 | 2.72 (1.24–5.96) | 0.01 | 2.28 (1.04–4.99) | 0.04 |
HR Hazard ratio, CI Confidence interval, RAASB Renin-angiotensin-aldosterone system blockades, BB Beta blockers, CCB Calcium channel blockers
aModel 1. Adjusted for clinicopathologic characteristics at the time of allograft IgAN; age, sex, CKD-EPI eGFR (categorical, < 15, ≥15 and 30, ≥30 and < 45, ≥45 and < 60, ≥60), albuminuria (none or trace, 1+, and ≥ 2+), mean arterial pressure (mmHg), pathologic components of the Oxford classification (M, E, S, T, and C components), presence of acute rejection at the time of recurrence
bModel 2. The adjustment variable of eGFR value at allograft IgAN diagnosis in above Model 1 was substituted for time-averaged eGFR within 3 months after diagnosis of allograft IgAN